TY - JOUR
T1 - Advanced stage ovarian cancer survival in Jakarta
AU - Purbadi, Sigit
AU - Tanamas, Gregorius
AU - Novianti, Lisa
N1 - Funding Information:
The authors did not receive any spesific grant from funding agencies in the public, commercial, or non-profit sectors. We thank the Department of Obstetrics and Gynecology, Cipto Mangunkusumo National Central Hospital and Faculty of Medicine, Universitas Indonesia for the opportunity given in writing this manuscript.
Publisher Copyright:
©2020 Purbadi et al.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/8/15
Y1 - 2020/8/15
N2 - Objective: Ovarian cancer is one of most common cancers among women and has high mortality rate. In Indonesia, most patients initially present with advanced stage disease. Several factors contribute to ovarian cancer survival rate. Here, we evaluate factors that contributed to ovarian cancer survival rate in our medical center. Materials and Methods: This is a retrospective study reporting on 128 advanced stage ovarian cancer cases in Dr. Cipto Mangunkusumo Central General Hospital, a national reference and teaching hospital in Jakarta, Indonesia. Patients were treated with cytoreductive surgery and chemotherapy, and followed for a five-year period. Univariate and multivariate survival analyses were performed to investigate the impact of age, parity, residual tumor, chemotherapy regimen, and lymph nodal status on overall survival. Results: In 51.6% of patients, surgery failed to achieve optimal debulking. The overall two and four year post-diagnosis survival rates were 28.7% and 9.4%, respectively. Uni-variate analysis revealed patient age, stage, histopathology, residual tumor, chemotherapy administration, but not the regimen and treatment completeness, impact patient survival. Multivariate analysis showed cancer stage (HR = 1.3, p = 0.04), and chemotherapy (HR = 2.8, p = 0.01) affected survival rate. Conclusion: Advanced stage ovarian cancer has a poor survival rate, especially in older patients. In this study, the only factors that impacted patient survival were cancer stage and adjuvant chemotherapy. Complex cytoreductive surgery in advanced stage ovarian cancer should also be performed to improve patient survival.
AB - Objective: Ovarian cancer is one of most common cancers among women and has high mortality rate. In Indonesia, most patients initially present with advanced stage disease. Several factors contribute to ovarian cancer survival rate. Here, we evaluate factors that contributed to ovarian cancer survival rate in our medical center. Materials and Methods: This is a retrospective study reporting on 128 advanced stage ovarian cancer cases in Dr. Cipto Mangunkusumo Central General Hospital, a national reference and teaching hospital in Jakarta, Indonesia. Patients were treated with cytoreductive surgery and chemotherapy, and followed for a five-year period. Univariate and multivariate survival analyses were performed to investigate the impact of age, parity, residual tumor, chemotherapy regimen, and lymph nodal status on overall survival. Results: In 51.6% of patients, surgery failed to achieve optimal debulking. The overall two and four year post-diagnosis survival rates were 28.7% and 9.4%, respectively. Uni-variate analysis revealed patient age, stage, histopathology, residual tumor, chemotherapy administration, but not the regimen and treatment completeness, impact patient survival. Multivariate analysis showed cancer stage (HR = 1.3, p = 0.04), and chemotherapy (HR = 2.8, p = 0.01) affected survival rate. Conclusion: Advanced stage ovarian cancer has a poor survival rate, especially in older patients. In this study, the only factors that impacted patient survival were cancer stage and adjuvant chemotherapy. Complex cytoreductive surgery in advanced stage ovarian cancer should also be performed to improve patient survival.
KW - Advanced stage ovarian cancer
KW - Chemotherapy
KW - Cytoreductive surgery
KW - Histopathology
KW - Residual tumor
KW - Survival rate
UR - http://www.scopus.com/inward/record.url?scp=85090983248&partnerID=8YFLogxK
U2 - 10.31083/J.EJGO.2020.04.5295
DO - 10.31083/J.EJGO.2020.04.5295
M3 - Article
AN - SCOPUS:85090983248
SN - 0392-2936
VL - 41
SP - 587
EP - 590
JO - European Journal of Gynaecological Oncology
JF - European Journal of Gynaecological Oncology
IS - 4
ER -